A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00477672 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

298

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease Psychosis

Interventions

DRUG: Pimavanserin tartrate (ACP-103)
DRUG: Pimavanserin tartrate (ACP-103)
DRUG: Placebo

Sponsor

ACADIA Pharmaceuticals Inc.